Mary Carberry

1.0k total citations
7 papers, 174 citations indexed

About

Mary Carberry is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mary Carberry has authored 7 papers receiving a total of 174 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mary Carberry's work include Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Cutaneous Melanoma Detection and Management (2 papers) and Gastric Cancer Management and Outcomes (2 papers). Mary Carberry is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Cutaneous Melanoma Detection and Management (2 papers) and Gastric Cancer Management and Outcomes (2 papers). Mary Carberry collaborates with scholars based in United States. Mary Carberry's co-authors include Peter J. O’Dwyer, Lydia Giles, Lynn M. Schuchter, Ravi K. Amaravadi, Michael B. Atkins, Kristi Gramlich, Amy Kramer, Andrea B. Troxel, Richard Letrero and David F. McDermott and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Mary Carberry

7 papers receiving 171 citations

Peers

Countries citing papers authored by Mary Carberry

Since Specialization

Citations

This map shows the geographic impact of Mary Carberry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Carberry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Carberry more than expected).

Fields of papers citing papers by Mary Carberry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Carberry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Carberry. The network helps show where Mary Carberry may publish in the future.

Co-authorship network of co-authors of Mary Carberry

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Carberry. A scholar is included among the top collaborators of Mary Carberry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Carberry. Mary Carberry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Landmark analysis of immunotherapy duration and disease free survival in advanced melanoma patients with a complete response. 2020 ·Journal of Clinical Oncology ·(unknown), Alexander C. Huang, Giorgos C. Karakousis, Wei Xu, Cathy Zheng, Mary Carberry, Lydia Giles, Kristin Kreider, Suzanne McGettigan, John N. Lukens, Lynn M. Schuchter, Ravi K. Amaravadi, Tara C. Mitchell	2
2	Abstract CT181: Safety, activity, and biomarkers for neoadjuvant anti-PD-1 therapy in melanoma 2018 ·Cancer Research ·Alexander C. Huang, (unknown), Robert Orlowski, Sangeeth M. George, Lakshmi Chilukuri, Andrew Kozlov, Mary Carberry, Lydia Giles, Suzanne McGettigan, Kristin Kreider, Jennifer H. Yearley, Lakshmanan Annamalai, Gerald P. Linette, Ravi K. Amaravadi, Lynn M. Schuchter, Michael D. Farwell, (unknown), Giorgos C. Karakousis, Tara C. Gangadhar	7
3	A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma 2013 ·Annals of Oncology ·Davendra Sohal, (unknown), Takeshi Uehara, Ursina Teitelbaum, Nevena Damjanov, Bruce J. Giantonio, Mary Carberry, Paul Wissel, (unknown), Peter J. O’Dwyer, Antonia R. Sepulveda, Weijing Sun	69
4	A phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report. 2012 ·Journal of Clinical Oncology ·Davendra Sohal, Ursina Teitelbaum, Takeshi Uehara, (unknown), Christopher D. Watt, Nevena Damjanov, Bruce J. Giantonio, Mary Carberry, Paul Wissel, (unknown), Peter J. O’Dwyer, Antonia R. Sepulveda, Weijing Sun	1
5	Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study. 2010 ·Journal of Clinical Oncology ·(unknown), (unknown), Ursina Teitelbaum, Nevena Damjanov, Daniel G. Haller, Bruce J. Giantonio, Mary Carberry, P J O’Dwyer	1
6	Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases 2009 ·Clinical Cancer Research ·Ravi K. Amaravadi, Lynn M. Schuchter, David F. McDermott, Amy Kramer, Lydia Giles, Kristi Gramlich, Mary Carberry, Andrea B. Troxel, Richard Letrero, Katherine L. Nathanson, Michael B. Atkins, Peter J. O’Dwyer, Keith T. Flaherty	89
7	Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma 2008 ·Journal of Clinical Oncology ·Leslie A. Fecher, (unknown), Keith T. Flaherty, Ravi K. Amaravadi, Lydia Giles, Suzanne McGettigan, Mary Carberry, D Elder, Lynn M. Schuchter	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact